Home＞ORGANIZATION
Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec(Dec.6.2016)
Japan should not make a hasty decision on the direction of its drug pricing reform without the pharmaceutical industry at the table, Jay Taylor, vice president of international affairs of the Pharmaceutical Research and Manufacturers of America (PhRMA), warned on December 2 ...
(LOG IN FOR FULL STORY)
-
-
Asian Industry Groups Agree to Use Common Site Master File for Plant Inspections
Apr.16
-
PhRMA Chief Warns of Serious Implications for Japan Market after 2018 Pricing Reform
Apr.13
-
Company Category Criteria for Price Maintenance Premium Tough on Ophthalmic Drug Makers: Industry Group
Apr.09
- Japan CRO Association Members Deliver Actual 8.1% Sales Surge in 2017 Apr.05
- GHIT Fund to Make New Investment of 1.66 Billion Yen for Development of Therapies and Vaccines Mar.30
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President(Apr.19)
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official(Apr.19)
